View Past PerformanceExpert.ai 대차대조표 건전성재무 건전성 기준 점검 4/6Expert.ai 의 총 주주 지분은 €25.1M 이고 총 부채는 €16.4M, 이는 부채 대 자기자본 비율을 65.4% 로 가져옵니다. 총자산과 총부채는 각각 €67.4M 및 €42.3M 입니다.핵심 정보65.38%부채/자본 비율€16.42m부채이자보상배율n/a현금€13.60m자본€25.12m총부채€42.26m총자산€67.38m최근 재무 건전성 업데이트업데이트 없음모든 업데이트 보기Recent updates공시 • Jan 30+ 1 more updateExpert.ai S.p.A. to Report First Half, 2026 Results on Sep 28, 2026Expert.ai S.p.A. announced that they will report first half, 2026 results on Sep 28, 2026공시 • Nov 26Expert.ai Presents EIX-Customer Screening for Intelligent Adverse News Monitoring in the Financial SectorExpert.ai released its enhanced solution for helping banks and financial institutions continuously monitor and analyze media coverage related to potential criminal activity or investigations involving customers. Available through the EidenAI Suite, Expert.ai's ecosystem of AI tools and solutions designed for industry, EIX-Customer Screening leverages advanced technologies to reinforce anti-money laundering (AML) programs and help organizations adopt a more proactive Know Your Customer (KYC) approach. With financial crime on the rise and regulatory requirements becoming increasingly stringent, EIX- Customer Screening automates the monitoring and analysis of news related to customers and counterparties--in real time and on a global scale. The solution significantly reduces false positives, streamlines oversight activities and improves operational efficiency. Powered by a Hybrid AI approach that combines cutting-edge capabilities, EIX-Customer Screened processes large volumes of multilingual news and unstructured data to help teams quickly detect critical events and adverse media, such as criminal activity, investigations or legal proceedings while drastically reducing false positives. The solution also supports sanctions screening and identification of politically exposed persons (PEPs), enhancing compliance and due diligence workflows for better accuracy and security. EIX-Customer Screening sets a new standard for AML and KYC programs. Built on Expert.ai's extensive technological expertise, deep domain knowledge and years of experience serving leading banking and financial organizations, the solution offers enhanced support for analysts by enabling: Continuous monitoring and analysis of global information flows (news, corporate records, regulatory lists, etc.) to deliver a complete, 360deg view of customer risk; Intelligent detection and classification across 60+ crime categories; Extraction of contextual data (e.g., age, role, location of individuals involved); Customizable relevance and risk scoring with up to 90% reduction in false positives, enabling teams to focus on true risks and accelerate AML investigations and customer onboarding; Screening against major global sanctions lists (UN, EU, OFAC, etc.) and PEP Checks and automatic generation of reports, alerts and summaries for AML/KYC teams. EIX-Customer Screened supports both large institutions and small organizations, making it easy to scale monitoring across the entire customer portfolio or targeted segments. The solution is available and integrates seamlessly with leading compliance platforms.공시 • Oct 15Expert.ai Strengthens Its Offering for the Insurance Industry with Advanced AI SolutionsExpert.ai announced significant enhancements to its insurance solutions available through the EidenAI Suite. The updates further strengthen Expert.ai's position as the trusted AI partner for insurers, MGAs, brokers and TPAs, delivering measurable value across core insurance functions and helping organizations accelerate processes, reduce risk and enable scalability across operations. The improved offering includes three specialized solutions that deliver measurable value across core insurance functions. All are available as turnkey and highly customized deployments with built-in governance and monitoring capabilities to ensure safe, transparent and compliant adoption of AI: AI-Powered Underwriting: Accuracy and speed in underwriting are essential for competitive advantage. EIX-Underwriting leverages its proven Hybrid AI approach to streamline data extraction from unstructured documents and risk evaluation, ensuring scalable performance even during peak demand periods. All commercial lines, both admitted and E&S, are supported. Claims Automation: Designed to eliminate bottlenecks in high-volume, document-intensive claims environments, Expert.ai's EIX-Claims Automation solution intelligently classifies and extracts critical data from incoming documents, speeding resolutions, reducing leakage, and improving customer satisfaction. The solution includes legal demand identification and medical summarization. Policy Servicing Automation: Outdated servicing processes often slow operations and create low customer satisfaction. Through EIX-Policy Servicing, Expert.ai helps teams automate workflows, such as endorsement, audit and renewal processing, end-to-end, while enhancing compliance, reducing operational costs and improving service delivery with intelligent, auditable processes.공시 • Oct 07Expert.ai Introduces New AI Solutions to Accelerate Pharma & Life Sciences InnovationExpert.ai announced the debut of its new AI-powered offerings designed to accelerate innovation across the pharmaceutical, healthcare and life sciences industries. Launched at BioTechX Europe 2025, Europe's largest congress dedicated to pharma & healthcare, the new solutions enable organizations to enhance data analysis, streamline discovery processes and unlock new possibilities for clinical trials and therapeutic improvement: EIX-Submission Readiness empowers teams to build smarter, more efficient workflows for regulatory documentation. EIX-Preclinical Document Intelligence streamlines preclinical documentation with greater speed and accuracy, free experts to focus on innovation. EIX-Clinical Trials Intelligence helps research teams to distill the most accurate, up-to-date information by disrupting across mountains of content from clinical registries, scientific publications and real-world data. EIX-IP Detection delivers comprehensive, explainable insights across patents, scientific literature and clinical trial data. Leveraging its deep domain expertise and unique hybrid AI approach, Expert.ai helps researchers transform the complexity of research & development into strategic advantage. By reducing manual effort and scaling insights from massive volumes of data, the new solutions use the most effective AI techniques to ensure regulatory accuracy, improve trial design, accelerate patient recruitment, reduce costs and minimize the constant risks of delays. With these innovations, Expert.ai continues to set the standard for applying AI in Pharma & Life Sciences, delivering greater efficiency and reliability across the life sciences value chain through intelligent document automation and AI agents.공시 • Sep 12Expert.Ai Launches Enhanced Solutions for Digital Information ServicesExpert.ai presents enhanced AI-powered solutions purpose-built for Digital Information Services. In data-saturated landscape, information services organizations must quickly convert vast, diverse streams of both structured and unstructured information into clear, actionable insights. Expert.ai empowers this transformation through advanced Hybrid AI capabilities that automate classification, entity and relationship extraction, tagging and semantic enrichment, similarity detection, and personalized recommendations. By extending content usability, Expert.ai maximizes the value of data, simplifying its governance and supporting continuous innovation through the best of diverse AI techniques -- including neuro-symbolic AI, AI agents, LLMs and the broader Generative AI ecosystem -- all tailored to extract meaning from complexity. Transforming how information services teams operate, Expert.ai streamlines workflows, enabling professionals to focus on high-value tasks, accelerate insight generation and repurpose knowledge across domains. New Expert.ai solutions for Digital Information Services include: EIX-Insight Discovery to cut through the noise, automatically identify meaningful insights from high-volume, high-complexity data sources and support research, editorial and business intelligence functions. EIX-Boosting Audience Engagement to use advanced personalization and intelligent content tagging to deliver more relevant, resonant experiences across channels, driving engagement and measurable growth. EIX-Insight Repurposing to transform previously published content and internal knowledge into new, high-value content assets, streamlining editorial operations and amplifying return on existing data. These new solutions are part of the EidenAI Suite, Expert.ai's modular AI ecosystem designed to support industry-specific challenges in media, insurance, pharma and life sciences, banking, financial services and more. With built-in explainability, governance and seamless integration, EidenAI Suite empowers organizations to scale language-based intelligence with speed, safety and precision.공시 • Jul 03+ 1 more updateExpert.ai S.p.A. (BIT:EXAI) acquired I.S.E.D. Ingegneria Dei Sistemi Elaborazione Dati Spa from S.& I. - Servizi Per L'Innovazione - S.R.L. Piu' Brevemente S.& I. - S.R.L. for €4.8 million.Expert.ai S.p.A. (BIT:EXAI) acquired I.S.E.D. Ingegneria Dei Sistemi Elaborazione Dati Spa from S.& I. - Servizi Per L'Innovazione - S.R.L. Piu' Brevemente S.& I. - S.R.L. for €4.8 million on July 1, 2025. The price of the acquisition is approximately €4.8 million (equity value) and will be settled in multiple tranches, distributed over different time periods, some of which will be after the completion of the partial demerger of S&I, as detailed below. The transaction has been fully financed through the use of internal funds. Through this acquisition, expert.ai strengthens its position in Public Administration and Digital Healthcare sectors. The shareholders of ISED, seizing the opportunity for the Company's development, have also decided to reinvest part of the proceeds from the sale of ISED into Expert.ai (the “ISED Investors”), committing to subscribe to a tranche of the Capital Increase reserved for them. The following are ISED's latest financial figures for the financial statements as of December 31, 2024: revenues of €8.8 million; EBITDA of €1.0 million with an EBITDA margin of 11%. The Board of Directors of Expert.ai Approved and simultaneously finalized the acquisition of 100% of th share capital of ISED S.p.A. Lexia acted as legal advisor and Rossella Lehnus, Emanuele Rita, Edoardo Tamburelli, Laura Caucci Molara and Andrea Gagliardi of Deloitte Financial Advisory S.r.l. acted as Financial Advisor to the Company. Scacchi Law Firm acted as legal advisor and ncesco Martinelli of Studio Martinelli acted as Financial Advisor to seller. The Caruso Andreatini Notai Associati firm , together with the lawyer Gabriella Pizzi , took care of the notarial profiles. Expert.ai S.p.A. (BIT:EXAI) completed the acquisition of I.S.E.D. Ingegneria Dei Sistemi Elaborazione Dati Spa from S.& I. - Servizi Per L'Innovazione - S.R.L. Piu' Brevemente S.& I. - S.R.L. on July 1, 2025.공시 • May 13Expert.ai S.p.A., Annual General Meeting, May 27, 2025Expert.ai S.p.A., Annual General Meeting, May 27, 2025, at 15:00 W. Europe Standard Time.공시 • Apr 08Expert.ai S.p.A. (BIT:EXAI) entered into a non-binding agreement to acquire 40% stake in Villanova Project from Tiscali Italia S.p.A.Expert.ai S.p.A. (BIT:EXAI) entered into a non-binding agreement to acquire 40% stake in Villanova Project from Tiscali Italia S.p.A on April 7, 2025. The non-binding agreement provides for (i) the establishment of a newco by Tiscali (the ‘NewCo’); (ii) the transfer of the Villanova Project to NewCo, and (iii) the subsequent investment by expert.ai in NewCo. Upon completion of the Transaction, it is expected that expert.ai will hold a stake equal to not less than 40% of NewCo's share capital. The Non-Binding Agreement provides for Tiscali's commitment, until June 30, 2025 unless expert.ai informs Tiscali that it does not wish to proceed with the Transaction not to engage in negotiations or discussions concerning the Project with parties other than expert.ai. The Transaction is contingent on the granting of any necessary authorizations by all relevant authorities and public bodies (including, but not limited to, the European Commission and MimiT) as well as the finalization of binding agreements.공시 • Feb 01+ 1 more updateExpert.ai S.p.A. to Report First Half, 2025 Results on Sep 30, 2025Expert.ai S.p.A. announced that they will report first half, 2025 results on Sep 30, 2025공시 • Jul 27Expert.ai S.p.A. has completed a Follow-on Equity Offering in the amount of €26.137109 million.Expert.ai S.p.A. has completed a Follow-on Equity Offering in the amount of €26.137109 million. Security Name: Ordinary Shares Security Type: Common Stock Securities Offered: 23,761,008 Price\Range: €1.1 Transaction Features: Rights Offering공시 • May 31Expert.ai S.p.A. announced that it expects to receive €1.2 million in fundingExpert.ai S.p.A. announced a private placement to issue common shares for the gross proceeds of €1,200,000 on May 30, 2024.공시 • Apr 16Expert.ai Launches Insight Engine for Life SciencesExpert.ai announced the launch of the expert.ai Insight Engine for Life Sciences. For the world of drug research and development, data is both a challenge to be managed and an opportunity to be leveraged. The ability to effectively and quickly mine scientific and biomedical content for developing new drugs and to design and operate clinical trials is more critical than ever before. The complexity of the diverse data sources that researchers depend on makes integrating, standardizing and analyzing them both challenging and time consuming. Commercial licensing and data access restrictions, as well as the lack of granularity and different taxonomies used by common search tools, further complicate the process. The convergence of these challenges in this fast-paced field impacts clinical research and delays drug development efforts, and it's precisely here that advanced AI technologies are adding significant value. Expert.ai Insight Engine for Life Sciences supports multiple use cases, including: Competitive Intelligence: Provide direct access to ongoing trials filtered for any combination of drug, indication, mechanism of action, sponsor or geography. Zoom into particular areas on the fly to gauge the competition's pipelines. Connect with both public and private research articles, research findings and emerging trends. Clinical Trial Design Optimization: Support clinical operations in optimizing the design and planning of a trial by identifying similar trials, comparing protocols, identifying suitable sites and patient populations, or assessing success criteria. This helps improve recruitment, allowing teams to compare design complexity based on inclusion/exclusion criteria and mine schedule of assessment data in protocol documents for site and patient burden assessments. Intellectual Property Protection: Automatically review patent claims against published papers and clinical trial activity, reducing the time that IP professionals spend on administrative activities and all IP-related tasks. Research Intelligence: Help researchers quickly access and analyze a vast amount of relevant information coming from biomedical and scientific literature, including full texts, speeding up the discovery and development of new drugs and therapies. As one of the finalists of the Bio-IT World"Best of Show" Awards, expert.ai will be showcasing its Insight Engine for Life Sciences at the Bio-IT World Conference & Expo in Boston (April 15-17, 2024), where a team of expert judges will view entries on site and choose winners based on the product's technical merit, functionality, innovation and in-person presentations.공시 • Apr 11Expert.ai S.p.A. to Report Fiscal Year 2023 Results on Apr 24, 2024Expert.ai S.p.A. announced that they will report fiscal year 2023 results on Apr 24, 2024공시 • Dec 13+ 2 more updatesExpert.ai S.p.A. to Report Fiscal Year 2023 Results on Mar 28, 2024Expert.ai S.p.A. announced that they will report fiscal year 2023 results on Mar 28, 2024공시 • Jul 08Expert.ai S.p.A., Annual General Meeting, Jul 24, 2023Expert.ai S.p.A., Annual General Meeting, Jul 24, 2023.공시 • Jan 31+ 2 more updatesExpert.ai S.p.A. to Report Fiscal Year 2022 Results on Mar 30, 2023Expert.ai S.p.A. announced that they will report fiscal year 2022 results on Mar 30, 2023재무 상태 분석단기부채: EXSP.F 의 단기 자산 ( €37.1M )이 단기 부채( €21.0M ).장기 부채: EXSP.F의 단기 자산(€37.1M)이 장기 부채(€21.3M)를 초과합니다.부채/자본 비율 추이 및 분석부채 수준: EXSP.F 의 순부채 대 자기자본 비율( 11.2% )은 satisfactory로 간주됩니다.부채 감소: EXSP.F의 부채 대비 자본 비율은 지난 5년 동안 132.1%에서 65.4%로 감소했습니다.대차대조표현금 보유 기간 분석과거에 평균적으로 손실을 기록해 온 기업의 경우, 최소 1년 이상의 현금 보유 기간이 있는지 평가합니다.안정적인 현금 활주로: EXSP.F 의 현재 여유 현금 흐름을 기준으로 충분한 현금 활주로가 있는지 판단하기에는 데이터가 부족합니다.예측 현금 활주로: EXSP.F 의 여유 현금 흐름이 역사적 비율에 따라 계속 증가하거나 감소하는 경우 충분한 현금 활주로가 있는지 판단하기에는 데이터가 부족합니다.건전한 기업 찾아보기7D1Y7D1Y7D1YSoftware 산업의 건실한 기업.View Dividend기업 분석 및 재무 데이터 상태데이터최종 업데이트 (UTC 시간)기업 분석2026/05/13 18:41종가2026/02/13 00:00수익2025/06/30연간 수익2024/12/31데이터 소스당사의 기업 분석에 사용되는 데이터는 S&P Global Market Intelligence LLC에서 제공됩니다. 아래 데이터는 이 보고서를 생성하기 위해 분석 모델에서 사용됩니다. 데이터는 정규화되므로 소스가 제공된 후 지연이 발생할 수 있습니다.패키지데이터기간미국 소스 예시 *기업 재무제표10년손익계산서현금흐름표대차대조표SEC 양식 10-KSEC 양식 10-Q분석가 컨센서스 추정치+3년재무 예측분석가 목표주가분석가 리서치 보고서Blue Matrix시장 가격30년주가배당, 분할 및 기타 조치ICE 시장 데이터SEC 양식 S-1지분 구조10년주요 주주내부자 거래SEC 양식 4SEC 양식 13D경영진10년리더십 팀이사회SEC 양식 10-KSEC 양식 DEF 14A주요 개발10년회사 공시SEC 양식 8-K* 미국 증권에 대한 예시이며, 비(非)미국 증권에는 해당 국가의 규제 서식 및 자료원을 사용합니다.별도로 명시되지 않는 한 모든 재무 데이터는 연간 기간을 기준으로 하지만 분기별로 업데이트됩니다. 이를 TTM(최근 12개월) 또는 LTM(지난 12개월) 데이터라고 합니다. 자세히 알아보기.분석 모델 및 스노우플레이크이 보고서를 생성하는 데 사용된 분석 모델에 대한 자세한 내용은 당사의 Github 페이지에서 확인하실 수 있습니다. 또한 보고서 활용 방법에 대한 가이드와 YouTube 튜토리얼도 제공합니다.Simply Wall St 분석 모델을 설계하고 구축한 세계적 수준의 팀에 대해 알아보세요.산업 및 섹터 지표산업 및 섹터 지표는 Simply Wall St가 6시간마다 계산하며, 프로세스에 대한 자세한 내용은 Github에서 확인할 수 있습니다.분석가 소스Expert.ai S.p.A.는 8명의 분석가가 다루고 있습니다. 이 중 2명의 분석가가 우리 보고서에 입력 데이터로 사용되는 매출 또는 수익 추정치를 제출했습니다. 분석가의 제출 자료는 하루 종일 업데이트됩니다.분석가기관Luca ArenaAlantra Capital Markets ResearchKatherine ThompsonEdison Investment ResearchDaniele AlibrandiStifel, Equities Research5명의 분석가 더 보기
공시 • Jan 30+ 1 more updateExpert.ai S.p.A. to Report First Half, 2026 Results on Sep 28, 2026Expert.ai S.p.A. announced that they will report first half, 2026 results on Sep 28, 2026
공시 • Nov 26Expert.ai Presents EIX-Customer Screening for Intelligent Adverse News Monitoring in the Financial SectorExpert.ai released its enhanced solution for helping banks and financial institutions continuously monitor and analyze media coverage related to potential criminal activity or investigations involving customers. Available through the EidenAI Suite, Expert.ai's ecosystem of AI tools and solutions designed for industry, EIX-Customer Screening leverages advanced technologies to reinforce anti-money laundering (AML) programs and help organizations adopt a more proactive Know Your Customer (KYC) approach. With financial crime on the rise and regulatory requirements becoming increasingly stringent, EIX- Customer Screening automates the monitoring and analysis of news related to customers and counterparties--in real time and on a global scale. The solution significantly reduces false positives, streamlines oversight activities and improves operational efficiency. Powered by a Hybrid AI approach that combines cutting-edge capabilities, EIX-Customer Screened processes large volumes of multilingual news and unstructured data to help teams quickly detect critical events and adverse media, such as criminal activity, investigations or legal proceedings while drastically reducing false positives. The solution also supports sanctions screening and identification of politically exposed persons (PEPs), enhancing compliance and due diligence workflows for better accuracy and security. EIX-Customer Screening sets a new standard for AML and KYC programs. Built on Expert.ai's extensive technological expertise, deep domain knowledge and years of experience serving leading banking and financial organizations, the solution offers enhanced support for analysts by enabling: Continuous monitoring and analysis of global information flows (news, corporate records, regulatory lists, etc.) to deliver a complete, 360deg view of customer risk; Intelligent detection and classification across 60+ crime categories; Extraction of contextual data (e.g., age, role, location of individuals involved); Customizable relevance and risk scoring with up to 90% reduction in false positives, enabling teams to focus on true risks and accelerate AML investigations and customer onboarding; Screening against major global sanctions lists (UN, EU, OFAC, etc.) and PEP Checks and automatic generation of reports, alerts and summaries for AML/KYC teams. EIX-Customer Screened supports both large institutions and small organizations, making it easy to scale monitoring across the entire customer portfolio or targeted segments. The solution is available and integrates seamlessly with leading compliance platforms.
공시 • Oct 15Expert.ai Strengthens Its Offering for the Insurance Industry with Advanced AI SolutionsExpert.ai announced significant enhancements to its insurance solutions available through the EidenAI Suite. The updates further strengthen Expert.ai's position as the trusted AI partner for insurers, MGAs, brokers and TPAs, delivering measurable value across core insurance functions and helping organizations accelerate processes, reduce risk and enable scalability across operations. The improved offering includes three specialized solutions that deliver measurable value across core insurance functions. All are available as turnkey and highly customized deployments with built-in governance and monitoring capabilities to ensure safe, transparent and compliant adoption of AI: AI-Powered Underwriting: Accuracy and speed in underwriting are essential for competitive advantage. EIX-Underwriting leverages its proven Hybrid AI approach to streamline data extraction from unstructured documents and risk evaluation, ensuring scalable performance even during peak demand periods. All commercial lines, both admitted and E&S, are supported. Claims Automation: Designed to eliminate bottlenecks in high-volume, document-intensive claims environments, Expert.ai's EIX-Claims Automation solution intelligently classifies and extracts critical data from incoming documents, speeding resolutions, reducing leakage, and improving customer satisfaction. The solution includes legal demand identification and medical summarization. Policy Servicing Automation: Outdated servicing processes often slow operations and create low customer satisfaction. Through EIX-Policy Servicing, Expert.ai helps teams automate workflows, such as endorsement, audit and renewal processing, end-to-end, while enhancing compliance, reducing operational costs and improving service delivery with intelligent, auditable processes.
공시 • Oct 07Expert.ai Introduces New AI Solutions to Accelerate Pharma & Life Sciences InnovationExpert.ai announced the debut of its new AI-powered offerings designed to accelerate innovation across the pharmaceutical, healthcare and life sciences industries. Launched at BioTechX Europe 2025, Europe's largest congress dedicated to pharma & healthcare, the new solutions enable organizations to enhance data analysis, streamline discovery processes and unlock new possibilities for clinical trials and therapeutic improvement: EIX-Submission Readiness empowers teams to build smarter, more efficient workflows for regulatory documentation. EIX-Preclinical Document Intelligence streamlines preclinical documentation with greater speed and accuracy, free experts to focus on innovation. EIX-Clinical Trials Intelligence helps research teams to distill the most accurate, up-to-date information by disrupting across mountains of content from clinical registries, scientific publications and real-world data. EIX-IP Detection delivers comprehensive, explainable insights across patents, scientific literature and clinical trial data. Leveraging its deep domain expertise and unique hybrid AI approach, Expert.ai helps researchers transform the complexity of research & development into strategic advantage. By reducing manual effort and scaling insights from massive volumes of data, the new solutions use the most effective AI techniques to ensure regulatory accuracy, improve trial design, accelerate patient recruitment, reduce costs and minimize the constant risks of delays. With these innovations, Expert.ai continues to set the standard for applying AI in Pharma & Life Sciences, delivering greater efficiency and reliability across the life sciences value chain through intelligent document automation and AI agents.
공시 • Sep 12Expert.Ai Launches Enhanced Solutions for Digital Information ServicesExpert.ai presents enhanced AI-powered solutions purpose-built for Digital Information Services. In data-saturated landscape, information services organizations must quickly convert vast, diverse streams of both structured and unstructured information into clear, actionable insights. Expert.ai empowers this transformation through advanced Hybrid AI capabilities that automate classification, entity and relationship extraction, tagging and semantic enrichment, similarity detection, and personalized recommendations. By extending content usability, Expert.ai maximizes the value of data, simplifying its governance and supporting continuous innovation through the best of diverse AI techniques -- including neuro-symbolic AI, AI agents, LLMs and the broader Generative AI ecosystem -- all tailored to extract meaning from complexity. Transforming how information services teams operate, Expert.ai streamlines workflows, enabling professionals to focus on high-value tasks, accelerate insight generation and repurpose knowledge across domains. New Expert.ai solutions for Digital Information Services include: EIX-Insight Discovery to cut through the noise, automatically identify meaningful insights from high-volume, high-complexity data sources and support research, editorial and business intelligence functions. EIX-Boosting Audience Engagement to use advanced personalization and intelligent content tagging to deliver more relevant, resonant experiences across channels, driving engagement and measurable growth. EIX-Insight Repurposing to transform previously published content and internal knowledge into new, high-value content assets, streamlining editorial operations and amplifying return on existing data. These new solutions are part of the EidenAI Suite, Expert.ai's modular AI ecosystem designed to support industry-specific challenges in media, insurance, pharma and life sciences, banking, financial services and more. With built-in explainability, governance and seamless integration, EidenAI Suite empowers organizations to scale language-based intelligence with speed, safety and precision.
공시 • Jul 03+ 1 more updateExpert.ai S.p.A. (BIT:EXAI) acquired I.S.E.D. Ingegneria Dei Sistemi Elaborazione Dati Spa from S.& I. - Servizi Per L'Innovazione - S.R.L. Piu' Brevemente S.& I. - S.R.L. for €4.8 million.Expert.ai S.p.A. (BIT:EXAI) acquired I.S.E.D. Ingegneria Dei Sistemi Elaborazione Dati Spa from S.& I. - Servizi Per L'Innovazione - S.R.L. Piu' Brevemente S.& I. - S.R.L. for €4.8 million on July 1, 2025. The price of the acquisition is approximately €4.8 million (equity value) and will be settled in multiple tranches, distributed over different time periods, some of which will be after the completion of the partial demerger of S&I, as detailed below. The transaction has been fully financed through the use of internal funds. Through this acquisition, expert.ai strengthens its position in Public Administration and Digital Healthcare sectors. The shareholders of ISED, seizing the opportunity for the Company's development, have also decided to reinvest part of the proceeds from the sale of ISED into Expert.ai (the “ISED Investors”), committing to subscribe to a tranche of the Capital Increase reserved for them. The following are ISED's latest financial figures for the financial statements as of December 31, 2024: revenues of €8.8 million; EBITDA of €1.0 million with an EBITDA margin of 11%. The Board of Directors of Expert.ai Approved and simultaneously finalized the acquisition of 100% of th share capital of ISED S.p.A. Lexia acted as legal advisor and Rossella Lehnus, Emanuele Rita, Edoardo Tamburelli, Laura Caucci Molara and Andrea Gagliardi of Deloitte Financial Advisory S.r.l. acted as Financial Advisor to the Company. Scacchi Law Firm acted as legal advisor and ncesco Martinelli of Studio Martinelli acted as Financial Advisor to seller. The Caruso Andreatini Notai Associati firm , together with the lawyer Gabriella Pizzi , took care of the notarial profiles. Expert.ai S.p.A. (BIT:EXAI) completed the acquisition of I.S.E.D. Ingegneria Dei Sistemi Elaborazione Dati Spa from S.& I. - Servizi Per L'Innovazione - S.R.L. Piu' Brevemente S.& I. - S.R.L. on July 1, 2025.
공시 • May 13Expert.ai S.p.A., Annual General Meeting, May 27, 2025Expert.ai S.p.A., Annual General Meeting, May 27, 2025, at 15:00 W. Europe Standard Time.
공시 • Apr 08Expert.ai S.p.A. (BIT:EXAI) entered into a non-binding agreement to acquire 40% stake in Villanova Project from Tiscali Italia S.p.A.Expert.ai S.p.A. (BIT:EXAI) entered into a non-binding agreement to acquire 40% stake in Villanova Project from Tiscali Italia S.p.A on April 7, 2025. The non-binding agreement provides for (i) the establishment of a newco by Tiscali (the ‘NewCo’); (ii) the transfer of the Villanova Project to NewCo, and (iii) the subsequent investment by expert.ai in NewCo. Upon completion of the Transaction, it is expected that expert.ai will hold a stake equal to not less than 40% of NewCo's share capital. The Non-Binding Agreement provides for Tiscali's commitment, until June 30, 2025 unless expert.ai informs Tiscali that it does not wish to proceed with the Transaction not to engage in negotiations or discussions concerning the Project with parties other than expert.ai. The Transaction is contingent on the granting of any necessary authorizations by all relevant authorities and public bodies (including, but not limited to, the European Commission and MimiT) as well as the finalization of binding agreements.
공시 • Feb 01+ 1 more updateExpert.ai S.p.A. to Report First Half, 2025 Results on Sep 30, 2025Expert.ai S.p.A. announced that they will report first half, 2025 results on Sep 30, 2025
공시 • Jul 27Expert.ai S.p.A. has completed a Follow-on Equity Offering in the amount of €26.137109 million.Expert.ai S.p.A. has completed a Follow-on Equity Offering in the amount of €26.137109 million. Security Name: Ordinary Shares Security Type: Common Stock Securities Offered: 23,761,008 Price\Range: €1.1 Transaction Features: Rights Offering
공시 • May 31Expert.ai S.p.A. announced that it expects to receive €1.2 million in fundingExpert.ai S.p.A. announced a private placement to issue common shares for the gross proceeds of €1,200,000 on May 30, 2024.
공시 • Apr 16Expert.ai Launches Insight Engine for Life SciencesExpert.ai announced the launch of the expert.ai Insight Engine for Life Sciences. For the world of drug research and development, data is both a challenge to be managed and an opportunity to be leveraged. The ability to effectively and quickly mine scientific and biomedical content for developing new drugs and to design and operate clinical trials is more critical than ever before. The complexity of the diverse data sources that researchers depend on makes integrating, standardizing and analyzing them both challenging and time consuming. Commercial licensing and data access restrictions, as well as the lack of granularity and different taxonomies used by common search tools, further complicate the process. The convergence of these challenges in this fast-paced field impacts clinical research and delays drug development efforts, and it's precisely here that advanced AI technologies are adding significant value. Expert.ai Insight Engine for Life Sciences supports multiple use cases, including: Competitive Intelligence: Provide direct access to ongoing trials filtered for any combination of drug, indication, mechanism of action, sponsor or geography. Zoom into particular areas on the fly to gauge the competition's pipelines. Connect with both public and private research articles, research findings and emerging trends. Clinical Trial Design Optimization: Support clinical operations in optimizing the design and planning of a trial by identifying similar trials, comparing protocols, identifying suitable sites and patient populations, or assessing success criteria. This helps improve recruitment, allowing teams to compare design complexity based on inclusion/exclusion criteria and mine schedule of assessment data in protocol documents for site and patient burden assessments. Intellectual Property Protection: Automatically review patent claims against published papers and clinical trial activity, reducing the time that IP professionals spend on administrative activities and all IP-related tasks. Research Intelligence: Help researchers quickly access and analyze a vast amount of relevant information coming from biomedical and scientific literature, including full texts, speeding up the discovery and development of new drugs and therapies. As one of the finalists of the Bio-IT World"Best of Show" Awards, expert.ai will be showcasing its Insight Engine for Life Sciences at the Bio-IT World Conference & Expo in Boston (April 15-17, 2024), where a team of expert judges will view entries on site and choose winners based on the product's technical merit, functionality, innovation and in-person presentations.
공시 • Apr 11Expert.ai S.p.A. to Report Fiscal Year 2023 Results on Apr 24, 2024Expert.ai S.p.A. announced that they will report fiscal year 2023 results on Apr 24, 2024
공시 • Dec 13+ 2 more updatesExpert.ai S.p.A. to Report Fiscal Year 2023 Results on Mar 28, 2024Expert.ai S.p.A. announced that they will report fiscal year 2023 results on Mar 28, 2024
공시 • Jul 08Expert.ai S.p.A., Annual General Meeting, Jul 24, 2023Expert.ai S.p.A., Annual General Meeting, Jul 24, 2023.
공시 • Jan 31+ 2 more updatesExpert.ai S.p.A. to Report Fiscal Year 2022 Results on Mar 30, 2023Expert.ai S.p.A. announced that they will report fiscal year 2022 results on Mar 30, 2023